Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033036 (APC)
 10,214 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred and twenty-five patients with advanced epithelial ovarian cancer (EOC) were postsurgically included in a multicentric clinical trial comparing the association of cisplatin (CDDP) (50 mg/m2 iv day1) + cyclophosphamide (CTX) (600 mg/m2 iv day 1) (PC regimen) versus the combination of PC + doxorubicin (ADM) (45 mg/m2 iv day 1) (PAC regimen), repeated every four weeks. After the sixth course of chemotherapy, patients without clinical evidence of disease or with surgically resectable residual disease (RD) underwent second-look laparotomy. Afterwards patients in surgical complete response (sCR) stopped chemotherapy, while partial responders or patients with stable disease received six more courses of the same regimen used as first-line treatment. Among the 67 patients with measurable RD, PAC regimen achieved a better clinical complete response (40.6% vs 20.0%); the difference approached statistical significance. In the 75 patients who underwent second-look laparotomy, PAC regimen induced a significantly higher sCR rate (62.2% vs 39.5%, p less than 0.05). The median survival (S) and progression free survival (PFS) were better in PAC arm, even if the differences were not statistically significant. Eight-year S and 8-year PFS were 32.7% and 24.7% respectively, for PAC arm, and 23.9% and 14.1%, respectively, for PC arm. These data seem to confirm the clinical advantage provided by the addition of ADM to PC regimen in the treatment of advanced EOC.
 ...
PMID:Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO). 151 12

From 1977 to 1981 39 patients with advanced ovarian carcinoma (stage III, IV, and relapses) were treated at the department of oncology. From 1977 to 1979 we followed to a great extent the ECOG protocol (EST 2875) which means combination chemotherapy by alternating cycles. Since 1980 we used for treatment the PAC I regimen. There was no obvious difference between the therapeutic results of regimen 1 (MTX/Thio followed by 5FU/CTX) and regimen 2 (MTX/Thio followed by VCR/ADM/5FU/CTX). The greatest complete remission rate (confirmed by a second-look laparotomy) was obtained by regimen 3 (PAC I). In 8 cases PAC I was used as a second line treatment. Only 3 partial remissions were seen.
 ...
PMID:[Therapeutic results in advanced ovarian cancer]. 641 61